Gamma Interpharm has commenced pharmaceutical exports to Cambodia, marking a significant step in the company’s six-decade history and expanding the international footprint of Sri Lanka’s pharmaceutical manufacturing sector.
Gamma Interpharm enters Cambodia as Sri Lankan pharmaceuticals reach a new regional market
The company launched its first exports to Cambodia on August 14, 2026, at its manufacturing facility in Sri Lanka, in the presence of stakeholders and employees. The milestone makes Gamma Interpharm the first truly Sri Lankan pharmaceutical manufacturing company to export pharmaceuticals to Cambodia, according to the company.
The entry into Cambodia forms part of a broader international expansion strategy aimed at establishing Sri Lankan-manufactured pharmaceutical products in regional overseas markets. For the company, the move represents more than access to a new destination; it also reflects its effort to position local pharmaceutical manufacturing capabilities within a wider Asian supply chain.
Gamma Interpharm has developed its manufacturing operations over six decades, with a heritage shaped by associations with Warner Lambert Inc. and Pfizer Inc. of the United States. During that period, the company has progressively strengthened its manufacturing, quality assurance and analytical capabilities.
The company said its latest export milestone has been supported by the vision and leadership of Chairman Kalana Hewamallika, whose focus has included creating new opportunities for Sri Lankan-manufactured pharmaceuticals in international markets.
Management and employees have also played an important role in supporting the company’s expansion plans. Gamma Interpharm operates with modern pharmaceutical manufacturing technology and advanced analytical capabilities, supported by a skilled workforce with international exposure.
The company has continued to invest in technology, employee training and global best practices as it works to strengthen its manufacturing capabilities and meet international quality expectations. Its manufacturing facility operates in compliance with World Health Organisation guidelines and has approval from Sri Lanka’s National Medicines Regulatory Authority.
Quality, safety and efficacy remain central to the company’s pharmaceutical manufacturing operations. These requirements are particularly important as local manufacturers seek to expand into overseas markets, where regulatory compliance and consistent manufacturing standards can influence market access and long-term competitiveness.
The Cambodia expansion therefore provides an important opportunity for Gamma Interpharm to demonstrate the capabilities developed through its long-standing presence in Sri Lanka’s pharmaceutical industry. It also adds another dimension to the country’s efforts to increase the value and international reach of locally manufactured pharmaceutical products.
The company’s regional strategy is aligned with its stated vision, “Seeking Excellence in contributing towards Quality Healthcare for All.” The objective reflects an emphasis on making quality pharmaceutical products available beyond the domestic market while developing a stronger international business presence.
Cambodia is expected to be an important starting point in the company’s next phase of regional expansion. Gamma Interpharm is already preparing to introduce its Sri Lankan-manufactured pharmaceuticals to Vietnam and the Philippines, according to the company.
The planned expansion into additional Asian markets could provide new opportunities for Sri Lanka’s pharmaceutical exports while allowing domestic manufacturers to diversify their international customer base. It also comes as pharmaceutical manufacturing becomes increasingly important to discussions around industrial development, import substitution and higher-value exports.
For Gamma Interpharm, the move into Cambodia builds on its established manufacturing base while opening a new avenue for regional growth. The company’s experience in pharmaceutical production, quality assurance and analytical testing provides a foundation for pursuing markets where regulatory and product-quality requirements are significant considerations.
The expansion also illustrates the potential for Sri Lankan manufacturers to move beyond supplying the domestic market and develop export-oriented operations. Establishing a presence in Cambodia, followed by planned entries into Vietnam and the Philippines, gives the company a pathway to broaden its regional reach over time.
The development is consequently significant not only for the company but also for Sri Lanka’s wider pharmaceutical manufacturing sector. Successful expansion into overseas markets can create opportunities for greater production, investment, skills development and participation in regional supply chains.
As Gamma Interpharm prepares for its next markets, the company’s ability to maintain quality standards while scaling production and navigating different regulatory environments will be important to its longer-term ambitions.
The Cambodia launch marks a new chapter in the company’s six-decade journey and strengthens the visibility of Sri Lanka pharmaceutical exports in the Asian market. With Vietnam and the Philippines identified as future destinations, the company is positioning its locally manufactured products for a broader regional presence.